SCHEMBL6915245

SCHEMBL6915245

Cn1nc(Br)nc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
CYP1A2 P05177 3/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
HTT P42858 2/20 0.48
MEN1 O00255 1/20 0.48
CYP2D6 P10635 1/20 0.48
KMT2A Q03164 1/20 0.48
PTGS2 P35354 1/20 0.46
HSD17B10 Q99714 2/20 0.45
CYP3A4 P08684 2/20 0.45
GABRA1 P14867 1/20 0.45
HPGD P15428 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9224003 0.82 ALDH1A1 (0.45) KDM4ECYP1A2ALDH1A1SMN1; SMN2CYP2C9
SCHEMBL27216894 0.81 SIGMAR1 (0.55) KDM4ESIGMAR1LMNA
SCHEMBL27888810 0.79 PTGS2 (0.46) KDM4ECYP1A2ALDH1A1SMN1; SMN2CYP2C9
SCHEMBL27888812 0.79 KMT2A (0.51) KDM4ECYP1A2ALDH1A1SMN1; SMN2CYP2C9
SCHEMBL27217204 0.76 NR1H3 (0.63) HTTMEN1KMT2AHSD17B10HPGD
SCHEMBL22095184 0.74 SIGMAR1 (0.80) KDM4EALDH1A1TMEM97SIGMAR1
SCHEMBL30056450 0.74 SIGMAR1 (0.80) KDM4EALDH1A1TMEM97SIGMAR1
SCHEMBL7306066 0.73 KDM4E (0.45) KDM4ECYP1A2ALDH1A1PTGS2HSD17B10
SCHEMBL22507230 0.72 MEN1 (0.54) KDM4EALDH1A1SMN1; SMN2HTTMEN1
SCHEMBL13835012 0.72 KIT (0.48) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9079886-B2 Substituted triazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-07-14 US disclosed
US-9079886-B2 Substituted triazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-07-14 US disclosed
EP-2523949-B1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICALS INC (US) 2014-08-20 EP disclosed
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-11-22 US disclosed
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-11-22 US disclosed
WO-2011086099-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A KDM4E 3415/4885CYP1A2 94/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.